Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - William Blair raised their FY2025 EPS estimates for Telix Pharmaceuticals in a report released on Tuesday, July 22nd. William Blair analyst A. Hsieh now forecasts that the company will post earnings of $0.55 per share for the year, up from their previous forecast of $0.49. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share.
A number of other equities analysts also recently weighed in on the company. HC Wainwright assumed coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They issued a "buy" rating and a $23.00 target price on the stock. Wedbush reissued an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th.
Get Our Latest Report on TLX
Telix Pharmaceuticals Stock Up 2.2%
TLX stock traded up $0.31 during trading on Thursday, reaching $14.20. The stock had a trading volume of 76,204 shares, compared to its average volume of 49,572. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. Telix Pharmaceuticals has a one year low of $13.61 and a one year high of $30.36. The company's 50 day moving average is $16.40 and its two-hundred day moving average is $16.96.
Institutional Investors Weigh In On Telix Pharmaceuticals
Several large investors have recently modified their holdings of the stock. Private Advisor Group LLC purchased a new stake in Telix Pharmaceuticals in the 1st quarter worth about $170,000. Blair William & Co. IL bought a new position in Telix Pharmaceuticals during the second quarter worth about $217,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Telix Pharmaceuticals in the second quarter worth about $297,000. Finally, ABC Arbitrage SA purchased a new position in shares of Telix Pharmaceuticals in the first quarter worth about $451,000.
Telix Pharmaceuticals Company Profile
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
